SCHEDULE: Ikarian Capital Discloses 11.4% Stake in Spruce Biosciences
Beneficial Ownership Report
Ikarian Capital, LLC and Neil Shahrestani have disclosed an 11.4% beneficial ownership stake in Spruce Biosciences Inc. common stock.
Summary
- Ikarian Capital, LLC and Neil Shahrestani jointly reported beneficial ownership of 121,356 shares of Spruce Biosciences Inc. common stock.
- This ownership represents 11.4% of the company's outstanding common stock.
- The percentage is based on 1,065,672 shares outstanding as of October 10, 2025, as disclosed in Spruce Biosciences' prospectus filed on October 29, 2025.
- Ikarian Capital, a Delaware limited liability company, is an investment adviser managing the Ikarian Healthcare Master Fund, L.P. and certain separate managed accounts.
- Neil Shahrestani, a U.S. citizen, indirectly controls Ikarian Capital and is therefore deemed to beneficially own the same securities.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 8
Explanation: The disclosure of a significant 11.4% stake by a specialized institutional investor like Ikarian Capital is generally viewed as a strong vote of confidence in the company's prospects, indicating a positive sentiment.
Positives
- The disclosure of a significant 11.4% beneficial ownership by an institutional investment adviser (Ikarian Capital, LLC) and its principal (Neil Shahrestani) indicates strong institutional confidence in Spruce Biosciences Inc.
Future Outlook
NA
Management Comments
- Neil Shahrestani, Sole Manager of Ikarian Capital, LLC, and Neil Shahrestani individually certified that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing reflects a significant institutional investment in a biotechnology company, a common occurrence as specialized funds seek to capitalize on growth opportunities within the sector. The substantial stake by Ikarian Capital, a healthcare-focused investment firm, suggests a belief in Spruce Biosciences' long-term potential within its specific therapeutic area.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract further investment, positively impacting share value.
Key Dates
| Date | Description |
|---|---|
| 2025-10-10 | Date as of which 1,065,672 shares of Common Stock were outstanding, used for calculating ownership percentage. |
| 2025-10-29 | Date of Issuer's prospectus filing with the SEC, disclosing shares outstanding. |
| 2025-10-31 | Date of event which required the filing of this statement. |
| 2025-11-07 | Date of signature for the Schedule 13G filing. |
Recommendation
buyThe disclosure of a significant 11.4% stake in Spruce Biosciences Inc. by Ikarian Capital, LLC, a registered investment adviser, signals strong institutional confidence in the company. Such a substantial position by a sophisticated investor often suggests a positive long-term outlook and could attract further investor interest, making it a potential 'buy' signal for other investors.
Keywords
Spruce Biosciences, Ikarian Capital, Beneficial Ownership, Institutional Investment, SEC Filing, Common Stock, Investment Adviser, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.